Representative images of cellular infectivity by the WA1 strain of SARS-CoV-2 in control-, proxalutamide-, or enzalutamide-treated conditions confirmed that decreased infection could be achieved by the AR antagonists proxalutamide and enzalutamide in LNCaP cells (Fig. 2C). The gene discussed is AR; the disease is infection.